MeiraGTx (NASDAQ:MGTXGet Rating) and SOPHiA GENETICS (NASDAQ:SOPHGet Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.


This table compares MeiraGTx and SOPHiA GENETICS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MeiraGTx -211.03% -39.79% -24.67%
SOPHiA GENETICS -182.14% -39.82% -32.83%

Insider & Institutional Ownership

67.7% of MeiraGTx shares are held by institutional investors. Comparatively, 27.6% of SOPHiA GENETICS shares are held by institutional investors. 13.3% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for MeiraGTx and SOPHiA GENETICS, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MeiraGTx 0 0 3 0 3.00
SOPHiA GENETICS 0 0 4 0 3.00

MeiraGTx presently has a consensus price target of $26.50, indicating a potential upside of 175.75%. SOPHiA GENETICS has a consensus price target of $20.67, indicating a potential upside of 281.30%. Given SOPHiA GENETICS’s higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than MeiraGTx.

Valuation & Earnings

This table compares MeiraGTx and SOPHiA GENETICS’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MeiraGTx $37.70 million 11.39 -$79.56 million ($1.81) -5.31
SOPHiA GENETICS $40.45 million 8.49 -$73.68 million N/A N/A

SOPHiA GENETICS has higher revenue and earnings than MeiraGTx.

MeiraGTx Company Profile (Get Rating)

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

SOPHiA GENETICS Company Profile (Get Rating)

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with's FREE daily email newsletter.